UNSPSC 51372020: Acetorphine

This classification denotes an analgesic agent with the molecular formula C27H35NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OGQ81529L, chemically known as 6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine 3-acetate but generally known as acetorphine, which bears US NIH Compound Identifier 62795. European Medicines Agency schedules Acetorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05226MIG. The term ACETORPHINE is an International Non-Proprietary Name.

UNSPSC 51372020 Acetorphine is a Commodity code that encompasses pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications being procured by state and local health agencies, cooperative purchasing alliances, and county health departments. Recent solicitations under this code show state and local governments buying opioid-reversal agents, generic pharmaceuticals, and OTC products for distribution through county health systems, state health and human services commissions, and multi-state purchasing cooperatives. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). Vendors must typically hold current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA approvals, and proof of legal authorization to work in the United States with E-Verify enrollment where required.

Recent opportunities include Seminole County's IFB60459723LAS issued June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: date discrepancy in source); the Texas Health and Human Services Commission's RFI No. HHS0017013 posted April 3, 2026, exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 issued January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract awards effective July 1, 2026. Geographic activity centers on Florida, Texas, and the Minnesota-led multi-state cooperative covering Oregon and other participating jurisdictions. Contracts typically require insurance minimums of $2 million to $5 million in general liability coverage, compliance with federal environmental and procurement regulations, and fixed-fee or net-price-based award structures with administrative fees ranging from three percent on cooperative purchases.